Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty

Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Benzamides / administration & dosage
  • Benzamides / adverse effects*
  • Benzamides / therapeutic use
  • Biomarkers / metabolism
  • Bone and Bones / drug effects*
  • Bone and Bones / metabolism*
  • Child
  • Female
  • Growth Charts*
  • Hormones / metabolism
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
  • Male
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Puberty / drug effects*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers
  • Hormones
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate